This blog is all about current FDA approved drugs to treat the hepatitis C virus (HCV) with a focus on treating HCV according to genotype, using information extracted from peer-reviewed journals, liver meetings/conferences, and interactive learning activities.
Risk Of Developing Liver Cancer After HCV Treatment
▼
Wednesday, April 27, 2011
Boceprevir "Live Feed" From The FDA Advisory Panel
Boceprevir is up for review today by the FDA advisory panel watch the live webcast here from FDA’s website, telaprevir is tomorrow. . .
No comments:
Post a Comment